Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New transplant strategy shows promise for blood cancer relapse

NCT ID NCT01208896

Disease control Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a stem cell transplant approach for adults with relapsed follicular lymphoma, a type of blood cancer. The treatment included the drug rituximab to help control the disease and prevent complications. The goal was to see if this strategy could improve survival and reduce side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

32 people

The number who actually took part.

Started

Feb 2011

Finished

Sep 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 and ≤ 65 years * Follicular lymphoma confirmed by a biopsy at the last relapse. * 2nd, 3rd or 4th complete or partial response according to Cheson's criteria 1 (Annexe 1) * Relapse after autologous-SCT except if the absence of autologous SCT is due to a failure of collecting peripheral stem cells or investigator decision to not proceed to the autologous graft because of serious criteria * Relapse after at least one line of treatment with rituximab * Karnofsky index \> 70% * HLA Matched related or unrelated donor (10/10 matching; HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQB1) * Signed informed consent Exclusion Criteria: * Stable or progressive disease according to Cheson's criteria1 (Annexe 1) * Absence of treatment with rituximab before the last relapse * Cardiac insufficiency (ejection fraction \< 50% by echocardiography) * Pulmonary disease characterized by DLCO \< 60% * Renal insufficiency (clearance of creatinin \< 60 ml/min) * Hepatic disease characterized by ASAT and/or ALAT and/or total bilirubin \> 2 times the upper normal value except in case of Gilbert's disease or hepatic lymphoma * HIV positive test * Bacterial, Viral or Fungal uncontrolled infections * Pregnant or breast feeding woman * Cancer in the last 5 years except in case of cutaneous baso-cellular cancer or epithelioma "in situ" of the uterine cervix

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lymphoma, follicular are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

follicular lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lymphoma, follicular Stem cell transplantation

Contacts and locations

Locations

  • APHP Hôpital Henri-Mondor

    Paris, 94010, France

  • APHP Hôpital Necker-Enfants malades

    Paris, 75015, France

  • APHP Hôpital Pitié-Salpêtrière

    Paris, 75651, France

  • APHP Hôpital Saint Louis

    Paris, 75475, France

  • CHRU Lille

    Lille, 59037, France

  • CHRU Tours

    Tours, 37000, France

  • CHU Grenoble

    Grenoble, 38043, France

  • CHU Limoges

    Limoges, 87042, France

  • CHU Nancy

    Nancy, 54511, France

  • CHU Poitiers - La Milétrie

    Poitiers, 86000, France

  • Centre Henri Becquerel

    Rouen, France

  • Département d'Hématologie et d'Oncologie, Hôpital CHRU de Hautepierre

    Strasbourg, 67098, France

  • Hôpital Edouard Herriot

    Lyon, 69374, France

  • Institut Gustave Roussy

    Villejuif, 94805, France

  • Institut de Cancérologie de la Loire

    Saint-Etienne, 60008, France

  • Service Hématologie Clinique, CHU -Hôtel Dieu

    Nantes, 44093, France

  • Service Hématologie Clinique, Hôpital Archet 1

    Nice, 06202, France

  • Service Hématologie Clinique, Hôpital Pontchaillou

    Rennes, 35033, France

  • Service Hématologie Oncologie, Hôpital Lapeyronie, CHU de Montpellier

    Montpellier, 34295, France

  • Service Hématologie et Thérapie cellulaire, Pavillon Villemin Pasteur, CHU Clermont-Ferrand

    Clermont-Ferrand, 63000, France

  • Service Hématologie, Hôpital Augustin Morvan

    Brest, 29609, France

  • Service Hématologie, Hôpital Minjoz

    Besançon, 25030, France

  • Service Hématologie, Hôpital Purpan

    Toulouse, 31059, France

  • Service des maladies du sang - Hôpital Haut-Lévêque - avenue de magellan

    Pessac, 33600, France

  • University Hospital Angers

    Angers, Angers, 49033, France

  • University Hospital, Caen

    Caen, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.